Volume Seventeen – Rapid and Novel Treatments in Psychiatry

Rapid and novel treatments in psychiatry: the future is now

Carolyn I. Rodriguez & Charles F. Zorumski

Finding new and better treatments for psychiatric disorders

No time to lose: the current state of research in rapid-acting psychotherapeutics

The Brain & Behavior Research Foundation’s philanthropic support for neuropsychiatric research

Navigating the FDA regulatory landscape

Are novel treatments for brain disorders hiding in plain sight?

Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward

Electronic health records and stratified psychiatry: bridge to precision treatment?

Ethical considerations in rapid and novel treatments in psychiatry

Ensuring psychedelic treatments and research do not leave anyone behind

Ketamine in neuropsychiatric disorders: an update

Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D. Henter & Carlos A. Zarate Jr

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

John H. Krystal, Ege T. Kavalali & Lisa M. Monteggia

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry

Jesse E. Hanson, Hongjie Yuan, Riley E. Perszyk, Tue G. Banke, Hao Xing, Ming-Chi Tsai, Frank S. Menniti & Stephen F. Traynelis

Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions

Riah Patterson, Irina Balan, A. Leslie Morrow & Samantha Meltzer-Brody

Neurosteroids: mechanistic considerations and clinical prospects

Jamie L. Maguire & Steven Mennerick

Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future

Scott M. Thompson

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer M. Mitchell & Brian T. Anderson

Therapeutic mechanisms of psychedelics and entactogens

Boris D. Heifets & David E. Olson

Psychedelics: preclinical insights provide directions for future research

Ryan H. Gumpper & Bryan L. Roth

Accelerated TMS - moving quickly into the future of depression treatment

Sanne J. H. van Rooij, Amanda R. Arulpragasam, William M. McDonald & Noah S. Philip

Closing the loop in psychiatric deep brain stimulation: physiology, psychometrics, and plasticity

Alik S. Widge

How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both?

Zhi-De Deng, Pei L. Robins, William Regenold, Paul Rohde, Moritz Dannhauer & Sarah H. Lisanby

Closed-loop neurostimulation for the treatment of psychiatric disorders

Kristin K. Sellers, Joshua L. Cohen, Ankit N. Khambhati, Joline M. Fan, A. Moses Lee, Edward F. Chang & Andrew D. Krystal

The future of brain circuit-targeted therapeutics

Shan H. Siddiqi, Sanaz Khosravani, John D. Rolston & Michael D. Fox

The why, when, where, how, and so what of so-called rapidly acting antidepressants

Alan F. Schatzberg & Sanjay J. Mathew

How should we design future mechanistic and/or efficacy clinical trials?

Maurizio Fava

Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments

Eric Lenze, John Torous & Patricia Arean

Advancing preclinical chronic stress models to promote therapeutic discovery for human stress disorders

Trevonn M. Gyles, Eric J. Nestler & Eric M. Parise

The role of neurotrophic factors in novel, rapid psychiatric treatments

Jihye Kim, Michelle J. He, Alina K. Widmann & Francis S. Lee

Antidepressants enter cells, organelles, and membranes

Zack Blumenfeld, Kallol Bera, Eero Castrén & Henry A. Lester

Novel mechanism-based treatments for pediatric anxiety and depressive disorders

Chad M. Sylvester, Joan L. Luby & Daniel S. Pine

Cell type specific focused ultrasound neuromodulation in preclinical models of sleep and psychiatric disorders

Keith R. Murphy & Luis de Lecea

Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipient

Kyle A. Brown & Todd D. Gould

Unraveling the cell-type-specific molecular pathways of PTSD: integrating GWAS with brain genomic profiling and in vitro modeling

Artemis Iatrou & Nikolaos P. Daskalakis

Potential applications of temporal interference deep brain stimulation for the treatment of transdiagnostic conditions in psychiatry

Negar Fani & Michael T. Treadway

Kynurenic acid: translational perspectives of a therapeutically targetable gliotransmitter

Ana Pocivavsek & Sophie Erhardt

Neurobiology and treatment advances for prolonged grief disorder

Zoe R. Donaldson & M. Katherine Shear

A novel rat model of potentiated incubation of opioid craving after abstinence induced by adverse consequences of drug seeking

Ida Fredriksson & Yavin Shaham

Herpesviruses and neuropsychiatric disorders: overlooked adversaries or innocent bystanders?

Haixia Zheng & Jonathan Savitz

Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine

Marjorie R. Levinstein & Michael Michaelides

Repurposing anti-inflammatory medications for alcohol and substance use disorders

Angela R. Ozburn & Sade M. Spencer

Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl

Cassandra D. Gipson & Justin C. Strickland

A path to novel, effective treatments for schizophrenia

Thomas W. Weickert & Cynthia Shannon Weickert

Moving beyond descriptive nosology: an argument for negative valence systems disorder

Elizabeth K. Lucas & Robert E. McCullumsmith

From high-throughput transcriptome characterization of individual synaptosomes to constructing the whole-brain connectome

Muchun Niu & Chenghang Zong

Swell1 channel-mediated tonic GABA release from astrocytes modulates cocaine reward

Junhua Yang & Zhaozhu Qiu

The orexin neurotransmitter system as a target for medication development for opioid use disorder

A. S. Huhn & K. E. Dunn

A unique role for cAMP signaling in microglia during opioid tolerance and withdrawal

Kevin R. Coffey & John F. Neumaier

Epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose

An T. Hoang & Olivia Corradin

Leveraging AI to predict substance use disorder treatment outcomes

Salvatore Giorgi & Brenda Curtis

The biological embedding of structural inequities: new insight from neuroscience

E. Kate Webb & Nathaniel G. Harnett

Potentiation of AMPA receptors for rapid therapeutic gain in psychiatry has reached a new level of excitement

Jeffrey M. Witkin & Arnold Lippa

Central amygdala CRF1 cells control nociception and anxiety-like behavior

Marcus M. Weera & Nicholas W. Gilpin

Gene–brain–behavior mechanisms underlying autism spectrum disorder: implications for precision psychiatry

Amanda M. Buch & Conor Liston

Microbes and mental health: translating preclinical findings to the clinic

Cherise R. Chin Fatt & Madhukar H. Trivedi

Towards personalized medicine: subtyping using functional profiles

Gunner Drossel & Anna Zilverstand

Postmortem-derived iPSC models in substance use disorders research

Emily Frances Mendez & Consuelo Walss-Bass

Transcranial focused ultrasound (tFUS): a promising noninvasive deep brain stimulation approach for pain

Bashar W. Badran & Xiaolong Peng